UBS AM
PTCT icon

UBS AM’s PTC Therapeutics PTCT Stock Holding History

UBS AM’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.65M Sell
126,963
-4,930
-4% -$349K ﹤0.01% 1263
2025
Q4 		$10M Buy
131,893
+1,995
+2% +$145K ﹤0.01% 1130
2025
Q3 		$7.97M Sell
129,898
-99,774
-43% -$5.2M ﹤0.01% 1154
2025
Q2 		$11.2M Buy
229,672
+50,917
+28% +$2.42M ﹤0.01% 1303
2025
Q1 		$9.11M Buy
178,755
+18,504
+12% +$923K ﹤0.01% 1270
2024
Q4 		$7.23M Buy
160,251
+26,274
+20% +$1.12M ﹤0.01% 1413
2024
Q3 		$4.97M Sell
133,977
-18,425
-12% -$617K ﹤0.01% 1574
2024
Q2 		$4.66M Buy
152,402
+73,305
+93% +$2.37M ﹤0.01% 1531
2024
Q1 		$2.3M Hold
79,097
– – ﹤0.01% 1626
2023
Q4 		$2.18M Buy
79,097
+3,371
+4% +$77.1K ﹤0.01% 1652
2023
Q3 		$1.7M Buy
75,726
+2,236
+3% +$83.2K ﹤0.01% 1709
2023
Q2 		$3.56M Hold
73,490
– – ﹤0.01% 1382
2023
Q1 		$3.56M Buy
73,490
+5,621
+8% +$257K ﹤0.01% 1382
2022
Q4 		$2.59M Sell
67,869
-194,100
-74% -$8.07M ﹤0.01% 1417
2022
Q3 		$13.2M Sell
261,969
-14,286
-5% -$700K 0.01% 872
2022
Q2 		$11.1M Sell
276,255
-190,951
-41% -$6.7M 0.01% 924
2022
Q1 		$17.4M Sell
467,206
-13,008
-3% -$501K 0.01% 877
2021
Q4 		$19.1M Buy
480,214
+2,904
+0.6% +$111K 0.01% 908
2021
Q3 		$17.8M Buy
477,310
+16,910
+4% +$695K 0.01% 901
2021
Q2 		$19.5M Buy
460,400
+144,198
+46% +$6.18M 0.01% 890
2021
Q1 		$15M Sell
316,202
-127,940
-29% -$7.6M 0.01% 951
2020
Q4 		$27.1M Buy
444,142
+16,702
+4% +$984K 0.01% 766
2020
Q3 		$20M Sell
427,440
-64,342
-13% -$3.17M 0.01% 763
2020
Q2 		$25M Buy
491,782
+123,696
+34% +$6.08M 0.02% 679
2020
Q1 		$16.4M Sell
368,086
-30,520
-8% -$1.54M 0.01% 724
2019
Q4 		$19.1M Buy
398,606
+27,378
+7% +$1.16M 0.01% 787
2019
Q3 		$12.6M Buy
371,228
+5,881
+2% +$256K 0.01% 883
2019
Q2 		$16.4M Buy
365,347
+58,247
+19% +$2.3M 0.01% 812
2019
Q1 		$11.6M Buy
307,100
+31,489
+11% +$1.06M 0.01% 891
2018
Q4 		$9.46M Buy
275,611
+17,367
+7% +$624K 0.01% 892
2018
Q3 		$12.1M Sell
258,244
-16,064
-6% -$665K 0.01% 886
2018
Q2 		$9.25M Sell
274,308
-28,800
-10% -$898K 0.01% 965
2018
Q1 		$8.2M Sell
303,108
-58,385
-16% -$1.48M 0.01% 986
2017
Q4 		$6.03M Buy
361,493
+32,396
+10% +$548K 0.01% 1049
2017
Q3 		$6.59M Sell
329,097
-58,800
-15% -$1.15M 0.01% 1003
2017
Q2 		$7.11M Sell
387,897
-228,060
-37% -$3.07M 0.01% 959
2017
Q1 		$6.06M Buy
615,957
+15,345
+3% +$186K 0.01% 987
2016
Q4 		$6.55M Sell
600,612
-7,465
-1% -$78.3K 0.01% 942
2016
Q3 		$8.52M Sell
608,077
-7,454
-1% -$60.6K 0.01% 912
2016
Q2 		$4.32M Sell
615,531
-20,769
-3% -$152K ﹤0.01% 1055
2016
Q1 		$4.1M Buy
636,300
+161,590
+34% +$2.8M ﹤0.01% 1077
2015
Q4 		$15.4M Sell
474,710
-19,218
-4% -$566K 0.02% 757
2015
Q3 		$13.2M Buy
493,928
+131,153
+36% +$5.61M 0.01% 804
2015
Q2 		$17.5M Buy
362,775
+54,175
+18% +$3.16M 0.02% 757
2015
Q1 		$18.8M Buy
308,600
+4,000
+1% +$244K 0.02% 727
2014
Q4 		$15.8M Buy
304,600
+31,000
+11% +$1.36M 0.02% 755
2014
Q3 		$12M Buy
+273,600
New +$8.56M 0.01% 791

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

UBS AM's PTCT Position: Q1 2026 in Review

UBS AM reduced its PTC Therapeutics (PTCT) stake by 3.7% in Q1 2026, selling an estimated $349K and leaving 126,963 shares worth $8.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

UBS AM first reported a position in PTCT in Q3 2014 and has held it in 47 quarters since. The position peaked at $27.1M in Q4 2020. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • UBS AM held 126,963 shares of PTC Therapeutics worth $8.65M as of Q1 2026.
  • UBS AM sold 4,930 PTC Therapeutics shares in Q1 2026, an estimated $349K.
  • PTC Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1263 holding.
  • UBS AM first reported a position in PTC Therapeutics in Q3 2014 and has held it in 47 quarters since.
  • UBS AM's PTC Therapeutics position peaked at $27.1M in Q4 2020.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.